• Miscellaneous musculoskeletal disorders

Voxzogo Generic Name & Formulations

General Description

Vosoritide 0.4mg, 0.56mg, 1.2mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free; contains trehalose dihydrate, mannitol.

Pharmacological Class

Human C type natriuretic peptide (CNP) analog.

How Supplied

Single-dose vials (2mL)—10 (w. prefilled diluent syringes, needles, syringes)

Generic Availability


Voxzogo Indications


To increase linear growth in children with achondroplasia and open epiphyses.

Voxzogo Dosage and Administration


Not applicable.


<5yrs: not established. Give by SC inj once daily (at same time each day) into middle of thighs, lower abdominal area, buttocks, or upper arms; rotate inj sites. Base dose on actual body weight. ≥5yrs (10–11kg): 0.24mg; (12–16kg): 0.28mg; (17–21kg): 0.32mg; (22–32kg): 0.4mg; (33–43kg): 0.5mg; (44–59kg): 0.6mg; (60–89kg): 0.7mg; (≥90kg): 0.8mg.

Voxzogo Contraindications

Not Applicable

Voxzogo Boxed Warnings

Not Applicable

Voxzogo Warnings/Precautions


Risk of transient decreases in BP. Ensure adequate food and fluid intake (~240–300mL) prior to initiation. Monitor body weight, growth, physical development regularly every 3–6 months. Permanently discontinue if no further growth potential due to closure of epiphyses. Renal impairment (eGFR <60mL/min/1.73m2): not recommended. Pregnancy. Nursing mothers.

Voxzogo Pharmacokinetics

See Literature

Voxzogo Interactions

Not Applicable

Voxzogo Adverse Reactions

Adverse Reactions

Inj site reactions (erythema, swelling, urticaria), vomiting, arthralgia, decreased BP, gastroenteritis, diarrhea, dizziness, ear pain, influenza.

Voxzogo Clinical Trials

See Literature

Voxzogo Note

Not Applicable

Voxzogo Patient Counseling

See Literature